Recently much emphasis is being laid on the development of microparticles because of their potential benefits such as increased bioavailability, reduced risk of systemic toxicity, reduced risk of local irritation and predictable gastric emptying. Objective: The objective of the present study is to prepare and evaluate mucoadhesive microparticles of chitosan-gliclazide for oral controlled release. Methods: A new method namely emulsification-desolvation-crosslinking was used for the preparation of chitosangliclazide microparticles and the microparticles were evaluated by in vitro and in vivo methods. Results: Spherical chitosan-gliclazide microparticles could be prepared by the emulsification-desolvation-crosslinking method. The method was reproducible with regard to size and size distribution of the microparticles. The chitosan-gliclazide microparticles exhibited good muoadhesive property. Gliclazide release from the chitosan microparticles was slow and extended over longer periods of time and depended on the proportion of core: coat. Gliclazide release from the chitosan microparticles was by diffusion mechanism. Microparticles (F3) prepared using a core: coat ratio of 8:2 gave slow and controlled release of gliclazide over 12 hr similar to that of commercial gliclazide SR tablets. In the in vivo evaluation, the gliclazide microparticles (F3) gave a slower reduction in serum glucose levels and the reduced glucose levels were sustained over longer periods of time. Conclusion: Microparticles (F3) are considered as a promising microparticulate drug delivery system for oral controlled release of gliclazide over 12 hr for b.i.d administration.
INTRODUCTION
Microparticles and microparticulate drug delivery systems are topics of current interest in drug delivery. The design, characterization advantages and applications of microparticles are reviewed in standard textbooks and articles. [1] [2] [3] [4] Design of microparticles requires a suitable polymer to serve the intended purpose. Examples of polymers used for the preparation of microparticles include cellulose nitrate, cellulose acetate, synthetic resins, ethyl cellulose, polystyrene, polyvinyl acetate, Eudragits, starch acetate, chitosan etc. In the present study chitosan, a mucoadhesive polymer was tried for the preparation of microparticles of gliclazide for oral controlled release. We have earlier reported 5 the preparation and in vitro evaluation of chitosan-gliclazide microparticles. Mucoadhesion is a topic of interest in the design of drug delivery systems and several studies reported [6] [7] [8] [9] [10] [11] [12] mucoadhesive drug delivery systems in the form of tablets, microcapsules, films, patches and gels for various routes. In the present study mucoadhesive microparticles of gliclazide were prepared using chitosan. The objective of the present study is to prepare and evaluate mucoadhesive chitosan-gliclazide microparticles by in vitro and in vivo methods. Gliclazide, a potential second generation short-acting sulfonylurea 13 requires formulation of controlled release systems for continuous therapeutic effect and better patient compliance by reducing the frequency of dosage administrations.
MATERIALS AND METHODS

Materials
Gliclazide was a gift sample from M/s Micro Labs, Pondicherry. Chitosan, 75-85 percent deacetylated was obtained from Central Institute of Fisheries Technology, Cochin, India. Sodium tri polyphosphate (Sigma), Acetic acid (Qualigens), Chloroform (Qualigens) and Soyabean oil were used. All other materials used were of pharmacopoeial grade.
Methods
Estimation of Gliclazide
Gliclazide was estimated by measuring absorbance at 227 nm in phosphate buffer of pH 7.4. Before using the method was validated for linearity range, accuracy, precision and interference by the excipients. The method exhibited linearity in the concentration range 1 -10 µg/ ml. The relative error and coefficient of variation (RSD) in the estimation were found to be 0.80% and 1.2% respectively. No interference by the excipients was observed.
Preparation of Chitosan-Gliclazide Microparticles
An emulsification-desolvation-crosslinking method was used for the preparation of chitosan-gliclazide microparticles, the details of which are as reported earliar. 5 Different proportions of core: coat namely 19:1 (F1), 9:1 (F2), 8:2 (F3) and 7:3 (F4) were used in the preparation of chitosan-gliclazide microparticles. The purpose of using different proportions of core: coat was to prepare microparticles with varying amount of coat polymer and to achieve different release rates.
Estimation of Drug Content and Encapsulation Efficiency
Four samples of 100mg each were taken from each batch of microparticles prepared and assayed for Size distribution analysis was done by sieving using a range of standard sieves.
Morphological Characterization by SEM
The surface morphology of microparticles was observed by scanning electron microscopy. The microparticles (F3) were vacuum dried. Before observation, samples were mounted on metal grids using double-sided adhesive tape, coated with gold palladium and observed microscopically using Joel, JSM-6360 LV scanning microscope. (Tokyo, Japan).
Drug Release Study
Release of gliclazide from the microparticles of size 30/50 mesh was evaluated in phosphate buffer of pH 7.4 (900 ml) using an 8-station dissolution rate test apparatus (model Disso-2000, M/s Lab. India) with a paddle stirrer (Apparatus 2) at 50 rpm and a temperature of 37°C ± 1°C. A sample of microparticles equivalent to 60 mg of gliclazide was used in each test. Each drug release experiment was replicated three times (n=3).
Analysis of Release Data
Drug release data were analyzed as per Zero order, First order, Higuchi 14 equation and Korsmeyer-Peppas 15 equation models.
Mucoadhesion Testing by in vitro Wash-Off Test
The mucoadhesive property of the microparticles (F3) was evaluated by an in vitro adhesion testing method known as the wash-off method. 16 The mucoadhesiveness of the microparticles was compared with that of nonbioadhesive material, ethylene vinyl acetate microparticles. Freshly excised pieces of intestinal mucosa (2 × 2 cm) from sheep were mounted onto glass slides (3 × 1 inch) with cyanoacrylate glue. Two glass slides were connected with a suitable support. Fifty microparticles were spread onto each wet rinsed tissue specimen and immediately thereafter the support was hung onto the arm of a USP tablet disintegrating test machine. When the disintegrating test machine was operated, the tissue specimen was given a slow, regular up-anddown movement in the test fluid at 37°C contained in a 1 L vessel of the machine. At the end of 30 min, at the end of 1 hr and at hourly intervals up to 12 hr, the machine was stopped and the number of microparticles still adhering to the tissue was counted. The test was performed at both gastric pH (0.1N HCl, pH 1.2) and intestinal pH (phosphate buffer, pH 6.8).
In vivo Evaluation
In vivo evaluation studies were conducted on (1) gliclazide and (2) mucoadhesive microparticles F3, in normal, healthy rabbits by measuring serum glucose levels following their oral administration at a dose equivalent to 3 mg/kg of gliclazide. The dose for experimental rabbits was calculated as suggested by Bikash Medhi and Ajay Prakash. 17 The experiments were conducted as per a crossover randomized block design (n=6).
In vivo study protocols were approved by Institutional Animal Ethics Committee (No. CPCSEA/CH/ ORG/2015-051). The products were administered orally the morning following overnight fasting. No food or liquid other than water was given during the experimental period. After the zero-hour blood sample (0.5 ml) was collected from the marginal ear vein, the product in the study was administered orally. Blood samples (0.5 mL) were collected from marginal ear vein at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 20, 24 hrs after administration. Serum glucose concentrations were determined by a known oxidase-peroxidase method 18 as described below employing a glucose kit supplied by Dr. Reddy's Laboratory, Diagnostic Division, Hyderabad, India. The method was revalidated and the relative standard deviation in the estimated values was found to be 1.2%. Blood samples collected were allowed to clot without any anticoagulant and were centrifuged immediately at 5000 rpm for 20 min to separate the serum. To the serum (0.02 mL) and standard (0.02 mL) in separate clean, dry test tubes, enzyme reagent (2 mL) was added, mixed well and incubated at 37°C for 10 min. The solutions were diluted to 5 mL with distilled water and the absorbance of the pink-colored solutions was measured in a spectrophotometer at 510 nm using a reagent blank. Serum glucose levels (mg/dL) and percentage reduction in serum glucose levels were calculated.
RESULTS AND DISCUSSION
Chitosan is sparingly soluble in water; practically insoluble in ethanol (95%) and other organic solvents. Chitosan dissolves readily in dilute and concentrated solutions acetic acid. In the present study chitosan was dissolved in 1% v/v acetic acid solution.
An emulsification-desolvation-crosslinking method 5 was used for the preparation of chitosan-gliclazide micro-particles. The method consists of emulsification of the chitosan solution in 1% v/v acetic acid containing the dispersed drug particles in an immiscible liquid medium (soya bean oil containing 10% chloroform) as microdroplets, followed by removal of the acetic acid from the polymer solution into chloroform by desolvation and crosslinking with tripolyphosphate and glutaraldehyde solution to form rigid microparticles. The microparticles were found to be discrete, spherical and free flowing. SEM of microparticles F3 is shown in Figure 1 .
The SEM photographs indicated that the microparticles were spherical and completely covered with the coat polymer. The sizes could be separated readily by sieving and a more uniform size range of microparticles could easily be obtained. The size analysis of different batches of microparticles showed that about 68-75% in each batch were in the size range 35/50 mesh (398.5µm).
The size of the microparticles in the method employed based on emulsification depends more on the speed of the stirrer, which was kept constant at 1000 rpm in the preparation of all products. More over the polymer chitosan is rapidly and completely dissolves in acetic acid solutions forming thin polymer solutions. In such a case the polymer concentration may not be influencing the size of microparticles. Hence though the percent coat polymer was increased the mean size of the microparticles remained almost the same. Size analysis of three batches of microparticles prepared under identical conditions indicated reproducibility of the method. Microparticles of the size 35/50 mesh (398.5µm) were selected for further evaluation. The physical characteristics of the microparticles prepared are given in and n values) in the analysis of release data as per various kinetic models are given in Table 2 . Gliclazide release from all the chitosan microparticles was slow and extended longer periods of time and depended on the proportion of coat in the microparticles. As the coat proportion was increased the release rate was decreased. A good linear relationship was observed between percent coat and release rate, k o (R² = 0.8448). The linear relationship could be described by the equation, y =11.849-0.3035x where x is percent coat and y is release rate (k o ).
The release data of all the formulations obeyed Korsmeyer Peppas equation model indicating that the drug release from the microparticles was by diffusion mechanism. The release exponent (n) was 0.24 and 0.40 in the case of formulation F1 and F2 respectively indicating Fickian diffusion was the release mechanism from these formulations. In the case of formulation F3 and F4 the release exponent (n) was 0.64 and 0.79 respectively indicating non-fickian (anomalous) diffusion was the release mechanism from these formulations. The drug release was by zero order diffusion mechanism (n=1.00) in the case of commercial product. Formulation F3 prepared using a core: coat ratio of 8:2 gave slow and controlled release of gliclazide over 12 h similar to that of commercial gliclazide SR tablets. The difference factor (f1=2.46) and similarity factor (f2=63.11) indicated that the drug release profiles of formulation F3 and commercial SR product are similar. The results of in vitro wash-off test are given in Table 3 . Microparticles (F3) exhibited good mucoadhesive properties in the in vitro wash-off test when compared to non-mucoadhesive material, ethylene vinyl acetate microparticles. The wash-off was slow in the case of microparticles (F3) when compared to that of ethylene vinyl acetate microparticles ( Table 3 ). The wash-off was faster in gastric pH 1.2 than in intestinal pH 6.8. Ch'ng et al. 19 observed that the pH of the medium was critical for the degree of hydration, solubility and mucoadhesion of the polymers. The relatively rapid wash-off of microparticles F3 observed at gastric pH 1.2 is due to ionization and solubility of chitosan at acidic pH. The results of the wash-off test indicated that the microparticles prepared had good mucoadhesive property.
In vivo evaluation
In vivo evaluation of the chitosan-gliclazide mucoadhesive microparticles was carried out in healthy, normal rabbits by measuring the hypoglycemic effect produced after their oral administration at a dose equivalent to 3 mg/kg of gliclazide, in comparison to gliclazide (pure drug) at the same dose. The serum glucose levels estimated and the percentage reduction in glucose levels following the oral administration of gliclazide pure drug and chitosan-gliclazide microparticles are given in Table 4 . When gliclazide was administered, a rapid reduction in serum glucose levels was observed; a maximum reduction of 55.3% was observed at 1.0 h after administration and the glucose levels recovered rapidly to the normal level within 6-8 h. In the case of microparticles, the reduction in glucose levels was slower; it reached maximum reduction (35.0%) at 3 h after administration and the reductions in glucose levels were sustained over longer periods of time. A 25% reduction in glucose levels is considered a significant hypoglycemic effect. 20 The hypoglycemic effect was maintained during the period from 0.5 hr to 4 hr following the administration of gliclazide pure drug, but the hypoglycemic effect was maintained during the period from 2 hr to 12 hr in the case of chitosan-gliclazide microparticles. The sustained hypoglycemic effect observed over longer periods of time in the case of microparticles is due to the slow release and absorption of gliclazide over longer periods of time. The hypoglycemic effect of gliclazide could be sustained over 12 hr with microparticles.
CONCLUSION
Chitosan-gliclazide mucoadhesive microparticles could be prepared by an emulsification-desolvation-crosslinking method. These microparticles exhibited good mucoadhesive property. Gliclazide release from the chitosan microparticles was slow and spread over longer periods of time. The drug release depended on the proportion of core: coat in the microparticles. Gliclazide release from the chitosan microparticles prepared was by diffusion mechanism. Microparticles (F3) prepared using a core: coat ratio of 8:2 gave slow and controlled release of gliclazide over 12 hr similar to that of commercial gliclazide SR tablets. In the in vivo evaluation these microparticles (F3) gave a slower reduction in serum glucose levels and the reduced glucose levels were sustained over longer periods of time. A significant hypoglycemic effect was maintained during 2-12 hr with these microparticles after their oral administration. As such microparticles (F3) are considered as a promising microparticulate DDS for oral controlled release of gliclazide over 12 hr for b.i.d administration.
